

Variable	Group	Statistic	Baseline	M6
Naïve CD4 (CCR7+CD45RA+) count (x10 ⁷ /L)	Placebo	Mean (SD) Median Min, Max	59.777 (26.108) 56.63 19.24, 121.155	7.733 (5.473) 6.929 0.1603, 19.933
	Palifermin	Mean (SD) Median Min, Max	44.333 (23.646) 45.126 9.996, 79.866	2.229 (1.997) 1.357 0.0189, 6.108

Interim Analysis Table 1: Showing naïve CD4 T cell counts at baseline and month 6 for the two arms of the study Placebo (n=14) vs Palifermin (n=14). Data show: mean (SD), median and minimum and maximum values.

Variable	Estimate	95% confidence interval	p-value
Intercept	5.294	0.948, 9.64	0.027
Treatment: Placebo vs. Palifermin	-5.132	-8.3, -1.964	0.005
Age (years)	-0.151	-0.353, 0.051	0.158
Baseline Naïve CD4+ T-cell count	0.051	-0.016, 0.118	0.154
Total Placebo/Palifermin dose	0.011	-0.033, 0.055	0.621

Interim Analysis Table 2: Results of multivariate linear regression demonstrating that Palifermin significantly reduces M6 naïve CD4 T cell counts compared to Placebo. Where age, baseline naïve CD4 count and total Palifermin dose are median-centred, the intercept represents the estimated naïve CD4 T-cell count at 6 months for a 31 year old patient receiving Placebo, with a baseline CD4 T-cell count of 4 and a total Palifermin dose of 155mg.